PROK ProKidney Corp.

ProKidney Corp. presented full results from its Phase 2 REGEN-007 trial of rilparencel at the American Society of Nephrology Kidney Week 2025. The study showed that rilparencel significantly slowed the progression of chronic kidney disease (CKD) in patients with advanced CKD and diabetes, with a 78% improvement in annual eGFR decline in Group 1. The treatment was well-tolerated, and over half of the patients for the Phase 3 accelerated approval analysis have been enrolled, with topline results anticipated in Q2 2027.

ProKidney Corp.'s Independent Director Brian Jude Pereira recently sold his entire holding in the company, netting approximately US$1.9 million. This significant insider sale, representing 100% of his shares at an average price of US$2.49, suggests a strong desire to reallocate capital, despite the sale price being above the current share price of US$2.41. The lack of recent insider purchases and a moderate insider ownership of 8.4% raise some caution regarding the company.

ProKidney announced its Q3 2025 financial results and provided updates on its clinical trials for rilparencel, a cell therapy for chronic kidney disease (CKD). Full Phase 2 REGEN-007 study results were presented at ASN Kidney Week 2025, demonstrating significant kidney function stabilization. Enrollment for the Phase 3 PROACT 1 study is over halfway complete, with topline results expected in Q2 2027, and the company ended the quarter with $272 million in cash, providing runway into mid-2027.

ProKidney Corp. announced positive Phase 2 results for its rilparencel treatment in patients with advanced chronic kidney disease and diabetes, showing significant improvement in kidney function. The company also provided an update on its Phase 3 PROACT 1 study, with over half of the required patients enrolled and topline results expected in Q2 2027. ProKidney reported strong financial liquidity with $272 million in cash and equivalents, sufficient to fund operations into mid-2027, despite a decrease from the previous year.

ProKidney Corp. announced it will present two posters at ASN Kidney Week 2025, including late-breaking Phase 2 REGEN-007 study results for renal autologous cell therapy in diabetes and CKD, and a characterization of its cell therapy candidate, rilparencel. These presentations aim to highlight the company's research progress in treating chronic kidney disease. The posters will be available on ProKidney's website after the event.

ProKidney Corp. announced positive Phase 2 trial results for rilparencel, an autologous cell therapy for advanced chronic kidney disease (CKD) and diabetes, which significantly slowed CKD progression and exhibited a favorable safety profile. Rilparencel is currently the only cell therapy in Phase 3 trials for this condition, with over half of the required patient enrollment complete and topline results anticipated by Q2 2027. These findings suggest rilparencel could offer a new therapeutic option to preserve kidney function and delay dialysis for high-risk patients.